Lanzi Ou Yicong Tang Yanming Deng Lijie Guo Qingqing He Tingting He Weineng Feng
10.3389/fonc.2022.911362
Front Oncol
2022 Jul 26;12:911362.
cux1-met fusion egfr mutations icotinib plus crizotinib lung adenocarcinoma partial response
CC BY
https://pubmed.ncbi.nlm.nih.gov/35957915/
Case Reports
PMC9360523
35957915
Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1- MET fusion
2022